Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: Doc Bones who wrote (72)	9/26/2002 7:19:12 PM
From: tuck	Read Replies (1) \| Respond to of 510

I'm over my head here, but I would think a resulting therapeutic would be part of a cocktail. CAF is not cytotoxic, rather it inhibits viral transcription, and as such is only part of the response that can suppress HIV. jvi.asm.org (this article attempts to elucidate CAF's mechanism of action, without knowing what its constituents are) Still, this would seem to put Dr. Ho's team on the cutting edge of the antiviral approach. Perhaps this explains the muted close by CIPH. There's a lot to do yet before a lead compound can be identified, as the article you cite notes. And then there's the IP issues surrounding defensins that Peter mentioned. Still I already liked CIPH for a number of reasons, and feel it's dirt cheap in the low $3s and under. Cheers, Tuck